Bernstein Sticks to Its Hold Rating for Pfizer (PFE)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Smith covers the Healthcare sector, focusing on stocks such as Pfizer, AstraZeneca, and arGEN X. According to TipRanks, Smith has an average return of 3.4% and a 50.00% success rate on recommended stocks.
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $28.38, which is a 10.77% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Hold rating on the stock with a $30.00 price target.
Based on Pfizer's latest earnings release for the quarter ending March 29, the company reported a quarterly revenue of $13.72 billion and a net profit of $2.97 billion. In comparison, last year the company earned a revenue of $14.88 billion and had a net profit of $3.12 billion
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
If You'd Invested $1,000 in PFE 5 Years Ago, Here's How Much You'd Have Today
Key Points Pfizer's stock is down over 60% from its December 2021 peak (as of Aug. 1). A drop in COVID-19 vaccines and treatment has caused a drop in Pfizer's revenue. Pfizer's stock appears to be in bargain territory for long-term investors. 10 stocks we like better than Pfizer › Five years ago, the world was in the thick of the COVID-19 global pandemic, bringing Pfizer (NYSE: PFE) into the spotlight because of the role it played in developing the COVID-19 vaccine with its partner BioNTech. It was able to get U.S. Food and Drug Administration (FDA) approval for its COVID-19 vaccine on Dec. 11, 2020, and it was released on Dec. 14, 2020. From mid-2020 to late 2021, Pfizer's stock skyrocketed, but since hitting its peak, it has reversed course. Had you invested $1,000 into Pfizer's stock on Aug. 1, 2020, your investment would only be worth around $638 as of Aug. 1, 2025. Pfizer's dividend would've cushioned some of the blow, but an investment then would still be less than your initial investment, at $828. Why has Pfizer's stock struggled the past few years? Much of Pfizer's stock price troubles since hitting its Dec. 21 peak come down to a decline in demand for its COVID-19 vaccine and treatments, anticipated patent expirations on drugs like Ibrance (breast cancer) and Eliquis (blood clots), and an underwhelming pipeline. All isn't lost with Pfizer's stock, however. At its current levels -- trading at 7.7 times forward earnings -- Pfizer seems to be flirting with bargain territory. I don't expect a quick turnaround, but this low valuation gives it more long-term upside than downside. It also helps that the stock's dividend yield sits above 7.3%, more than 5.5 times the S&P 500 average. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Stefon Walters has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in PFE 5 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Pfizer (NYSE:PFE) Reports Upbeat Q2
Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q2 CY2025, with sales up 10.3% year on year to $14.65 billion. The company expects the full year's revenue to be around $62.5 billion, close to analysts' estimates. Its non-GAAP profit of $0.78 per share was 35.9% above analysts' consensus estimates. Is now the time to buy Pfizer? Find out in our full research report. Pfizer (PFE) Q2 CY2025 Highlights: Revenue: $14.65 billion vs analyst estimates of $13.58 billion (10.3% year-on-year growth, 7.9% beat) Adjusted EPS: $0.78 vs analyst estimates of $0.57 (35.9% beat) The company reconfirmed its revenue guidance for the full year of $62.5 billion at the midpoint Management raised its full-year Adjusted EPS guidance to $3 at the midpoint, a 3.4% increase Operating Margin: 20.8%, down from 22.4% in the same quarter last year Organic Revenue rose 10% year on year (3% in the same quarter last year) Market Capitalization: $133.8 billion Company Overview With roots dating back to 1849 when two German immigrants opened a fine chemicals business in Brooklyn, Pfizer (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a wide range of diseases and conditions. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, Pfizer's sales grew at a decent 8.2% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Pfizer's recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 9.8% over the last two years. Pfizer also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, Pfizer's organic revenue averaged 5.2% year-on-year declines. Because this number is better than its two-year revenue growth, we can see that some mixture of divestitures and foreign exchange rates dampened its headline results. This quarter, Pfizer reported year-on-year revenue growth of 10.3%, and its $14.65 billion of revenue exceeded Wall Street's estimates by 7.9%. Looking ahead, sell-side analysts expect revenue to decline by 3.3% over the next 12 months. Although this projection is better than its two-year trend, it's hard to get excited about a company that is struggling with demand. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Pfizer's operating margin has risen over the last 12 months and averaged 29.9% over the last five years. On top of that, its profitability was top-notch for a healthcare business, showing it's an well-run company with an efficient cost structure. Analyzing the trend in its profitability, Pfizer's operating margin of 25.9% for the trailing 12 months may be around the same as five years ago, but it has decreased by 7.3 percentage points over the last two years. This dynamic unfolded because it failed to adjust its fixed costs while demand fell. This quarter, Pfizer generated an operating margin profit margin of 20.8%, down 1.6 percentage points year on year. This reduction is quite minuscule and indicates the company's overall cost structure has been relatively stable. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Pfizer's EPS grew at an unimpressive 3.3% compounded annual growth rate over the last five years, lower than its 8.2% annualized revenue growth. However, its operating margin didn't change during this time, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings. Diving into the nuances of Pfizer's earnings can give us a better understanding of its performance. A five-year view shows Pfizer has diluted its shareholders, growing its share count by 1.5%. This has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals. In Q2, Pfizer reported adjusted EPS at $0.78, up from $0.60 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Pfizer's full-year EPS of $3.39 to shrink by 15%. Key Takeaways from Pfizer's Q2 Results We were impressed by how significantly Pfizer blew past analysts' organic revenue expectations this quarter. We were also excited its EPS outperformed Wall Street's estimates by a wide margin. On the other hand, its full-year EPS guidance was in line. Zooming out, we think this was a solid print. The stock traded up 1.9% to $23.99 immediately after reporting. Indeed, Pfizer had a rock-solid quarterly earnings result, but is this stock a good investment here? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Pfizer lifts annual profit outlook as Q2 results come ahead, shares gain
-- Pfizer posted second-quarter earnings and revenue that exceeded analyst estimates and raised its full-year profit outlook, pushing its shares over 3% higher in premarket trading. The pharmaceutical giant reported Q2 earnings per share (EPS) of $0.78, well ahead of the $0.57 consensus. Revenue for the period increased by 10% to $14.7 billion, also topping expectations of $13.47 billion. 'Pfizer had another strong quarter of focused execution and we're pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins," said Dr. Albert Bourla, Chairman and CEO of Pfizer. The company raised its full-year adjusted EPS outlook by $0.10 at the midpoint, now guiding to a range of $2.90 to $3.10, compared to the $3.01 consensus. Full-year revenue guidance was reaffirmed at $61.0 to $64.0 billion. Pfizer said the revised profit outlook reflects strong results in the first half of the year, improved cost efficiency, a lower tax rate, and favorable currency moves. It also factors in a one-time $1.35 billion R&D charge tied to a licensing deal with 3SBio, which is expected to reduce third-quarter EPS by about $0.20. The company said its guidance already accounts for current tariffs and potential drug pricing actions following a letter from President Trump in late July. Related articles Pfizer lifts annual profit outlook as Q2 results come ahead, shares gain These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia 7 Undervalued Stocks on the Rise With 50%+ Upside Potential Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
